Ionis partners with Metagenomi to add gene editing to its broad technology platform
- Collaboration with a leader in gene editing systems is Ionis' latest move to expand and diversify its technology
- CRISPR-Cas gene editing is a natural extension of Ionis' innovative approach to delivering potentially transformative therapies
- Ionis to hold webcast
Nov. 14at 8 a.m. Eastern Time
"Ionis was founded over 30 years ago to discover and develop novel, highly personalized medicines using our powerful RNA-targeting technology platform. This partnership with Metagenomi supports Ionis' strategic objective to advance our technology and expand our capabilities to deliver precision genetic medicines. Together, we can broaden the application of gene editing by leveraging Ionis' vast experience in nucleic acid therapeutics to optimize and extend the reach of gene editing for liver targets and to new tissues," said Ionis Chief Executive Officer
"Gene editing has the potential to transform chronic therapies into potentially curative treatments for patients who currently have limited options," said
Under the terms of the agreement, Ionis will pay
Ionis will conduct a webcast on
CRISPR Gene Editing
CRISPR (clustered regularly interspaced short palindromic repeats) gene editing is a technology that modifies the sequence of DNA in cells utilizing a specific RNA-guided nuclease (Cas enzyme). Gene editing enzymes act as molecular word processors to correct the genetic code at the precise spot where it is malfunctioning.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.
To learn more about Ionis, visit www.ionispharma.com and follow us on Twitter @ionispharma.
Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines and can be leveraged by partners. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co/.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding our collaboration and license agreement with
Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-partners-with-metagenomi-to-add-gene-editing-to-its-broad-technology-platform-301676345.html
Ionis Investor Contact: firstname.lastname@example.org, 760-603-2331; Ionis Media Contact: email@example.com, 760-603-4679; Metagenomi Investor Contact: Simon Harnest, firstname.lastname@example.org, +1 (917) 403-1051; Metagenomi Media Contact: Ashlye Hodge, email@example.com, +1 (510) 734-4409